{"brief_title": "A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs", "brief_summary": "To evaluate the tolerance, and comparative virologic and immunologic effects of the two combination regimens.", "detailed_description": "100 patients will be randomized to receive Zerit (Stavudine) + Epivir (Lamivudine) + Crixivan (Indinavir) and 100 patients will be randomized to receive Retrovir (Zidovudine) + Epivir (Lamivudine) + Crixivan (Indinavir). Patients will be treated for 48 weeks.", "condition": ["HIV Infections"], "intervention_type": ["Drug", "Drug", "Drug", "Drug"], "intervention_name": ["Indinavir sulfate", "Lamivudine", "Stavudine", "Zidovudine"], "criteria": "Inclusion Criteria Patients must have: - Documented HIV infection. - CD4 cell count of 200 - 700 cells/mm3. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: AIDS defining condition within 1 month of study entry. Prior Medication: Excluded: Patients with any history of antiretroviral therapy treatment.", "gender": "All", "minimum_age": "16 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Viral Load", "mesh_term": ["HIV Infections", "Stavudine", "Zidovudine", "Lamivudine", "Indinavir"], "id": "NCT00002369"}